Market Overview

Perrigo Buys Remaining Stake in Cobrek Pharma for ~$45M

Share:
Related PRGO
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Could M&A Boost Pfizer More? Jefferies Thinks So
The Love Triangle In Generic Drugs (Seeking Alpha)

Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 million on a cash free and debt free basis.

Posted-In: News M&A

 

Related Articles (PRGO)

Around the Web, We're Loving...

Get Benzinga's Newsletters